Literature DB >> 27899655

Visualization of self-delivering hydrophobically modified siRNA cellular internalization.

Socheata Ly1,2, Deanna M Navaroli1, Marie-Cécile Didiot1,2, James Cardia3, Lakshmipathi Pandarinathan3, Julia F Alterman1,2, Kevin Fogarty1, Clive Standley1, Lawrence M Lifshitz1, Karl D Bellve1, Matthieu Prot1, Dimas Echeverria1,2, Silvia Corvera4, Anastasia Khvorova5,2.   

Abstract

siRNAs are a new class of therapeutic modalities with promising clinical efficacy that requires modification or formulation for delivery to the tissue and cell of interest. Conjugation of siRNAs to lipophilic groups supports efficient cellular uptake by a mechanism that is not well characterized. Here we study the mechanism of internalization of asymmetric, chemically stabilized, cholesterol-modified siRNAs (sd-rxRNAs®) that efficiently enter cells and tissues without the need for formulation. We demonstrate that uptake is rapid with significant membrane association within minutes of exposure followed by the formation of vesicular structures and internalization. Furthermore, sd-rxRNAs are internalized by a specific class of early endosomes and show preferential association with epidermal growth factor (EGF) but not transferrin (Tf) trafficking pathways as shown by live cell TIRF and structured illumination microscopy (SIM). In fixed cells, we observe ∼25% of sd-rxRNA co-localizing with EGF and <5% with Tf, which is indicative of selective endosomal sorting. Likewise, preferential sd-rxRNA co-localization was demonstrated with EEA1 but not RBSN-containing endosomes, consistent with preferential EGF-like trafficking through EEA1-containing endosomes. sd-rxRNA cellular uptake is a two-step process, with rapid membrane association followed by internalization through a selective, saturable subset of the endocytic process. However, the mechanistic role of EEA1 is not yet known. This method of visualization can be used to better understand the kinetics and mechanisms of hydrophobic siRNA cellular uptake and will assist in further optimization of these types of compounds for therapeutic intervention.
© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27899655      PMCID: PMC5224471          DOI: 10.1093/nar/gkw1005

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  81 in total

Review 1.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.

Authors:  Richard S Geary; Daniel Norris; Rosie Yu; C Frank Bennett
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

2.  Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye.

Authors:  Michael Byrne; Radouil Tzekov; Yi Wang; Amanda Rodgers; James Cardia; Glenna Ford; Katherine Holton; Lakshmipathi Pandarinathan; Jennifer Lapierre; William Stanney; Karen Bulock; Sharon Shaw; Lyn Libertine; Kevin Fettes; Anastasia Khvorova; Shalesh Kaushal; Pamela Pavco
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-01       Impact factor: 2.671

3.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

4.  Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking.

Authors:  Inger Helene Madshus; Espen Stang
Journal:  J Cell Sci       Date:  2009-10-01       Impact factor: 5.285

5.  Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.

Authors:  M DiFiglia; M Sena-Esteves; K Chase; E Sapp; E Pfister; M Sass; J Yoder; P Reeves; R K Pandey; K G Rajeev; M Manoharan; D W Y Sah; P D Zamore; N Aronin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-16       Impact factor: 11.205

Review 6.  Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor.

Authors:  A Dautry-Varsat
Journal:  Biochimie       Date:  1986-03       Impact factor: 4.079

7.  Regarding the amazing choreography of clathrin coats.

Authors:  Linton M Traub
Journal:  PLoS Biol       Date:  2011-03-22       Impact factor: 8.029

8.  A status report on RNAi therapeutics.

Authors:  Akshay K Vaishnaw; Jared Gollob; Christina Gamba-Vitalo; Renta Hutabarat; Dinah Sah; Rachel Meyers; Tony de Fougerolles; John Maraganore
Journal:  Silence       Date:  2010-07-08

9.  Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group.

Authors:  Natalya S Petrova; Ivan V Chernikov; Mariya I Meschaninova; Iiya S Dovydenko; Aliya G Venyaminova; Marina A Zenkova; Valentin V Vlassov; Elena L Chernolovskaya
Journal:  Nucleic Acids Res       Date:  2011-11-10       Impact factor: 16.971

10.  Silencing by small RNAs is linked to endosomal trafficking.

Authors:  Young Sik Lee; Sigal Pressman; Arlise P Andress; Kevin Kim; Jamie L White; Justin J Cassidy; Xin Li; Kim Lubell; Do Hwan Lim; Ik Sang Cho; Kenji Nakahara; Jonathan B Preall; Priya Bellare; Erik J Sontheimer; Richard W Carthew
Journal:  Nat Cell Biol       Date:  2009-08-16       Impact factor: 28.824

View more
  37 in total

1.  The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.

Authors:  Annabelle Biscans; Andrew Coles; Dimas Echeverria; Anastasia Khvorova
Journal:  J Control Release       Date:  2019-03-30       Impact factor: 9.776

2.  Modulation of PDCD1 exon 3 splicing.

Authors:  Junjie Sun; Jialin Bai; Tao Jiang; Yuan Gao; Yimin Hua
Journal:  RNA Biol       Date:  2019-08-28       Impact factor: 4.652

Review 3.  Improving siRNA Delivery In Vivo Through Lipid Conjugation.

Authors:  Maire F Osborn; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2018-05-10       Impact factor: 5.486

Review 4.  Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't.

Authors:  R L Juliano
Journal:  Nucleic Acid Ther       Date:  2018-04-30       Impact factor: 5.486

5.  Hydrophobicity of Lipid-Conjugated siRNAs Predicts Productive Loading to Small Extracellular Vesicles.

Authors:  Annabelle Biscans; Reka A Haraszti; Dimas Echeverria; Rachael Miller; Marie-Cecile Didiot; Mehran Nikan; Loic Roux; Neil Aronin; Anastasia Khvorova
Journal:  Mol Ther       Date:  2018-04-04       Impact factor: 11.454

6.  Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs.

Authors:  Taisia Shmushkovich; Kathryn R Monopoli; Diana Homsy; Dmitriy Leyfer; Monica Betancur-Boissel; Anastasia Khvorova; Alexey D Wolfson
Journal:  Nucleic Acids Res       Date:  2018-11-16       Impact factor: 16.971

7.  Optimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles.

Authors:  Reka Agnes Haraszti; Rachael Miller; Marie-Cecile Didiot; Annabelle Biscans; Julia F Alterman; Matthew R Hassler; Loic Roux; Dimas Echeverria; Ellen Sapp; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Mol Ther       Date:  2018-06-21       Impact factor: 11.454

8.  Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay.

Authors:  Bruno M D C Godinho; James W Gilbert; Reka A Haraszti; Andrew H Coles; Annabelle Biscans; Loic Roux; Mehran Nikan; Dimas Echeverria; Matthew Hassler; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2017-10-12       Impact factor: 5.486

9.  A High-throughput Assay for mRNA Silencing in Primary Cortical Neurons in vitro with Oligonucleotide Therapeutics.

Authors:  Julia F Alterman; Andrew H Coles; Lauren M Hall; Neil Aronin; Anastasia Khvorova; Marie-Cécile Didiot
Journal:  Bio Protoc       Date:  2017-08-20

10.  Loading of Extracellular Vesicles with Chemically Stabilized Hydrophobic siRNAs for the Treatment of Disease in the Central Nervous System.

Authors:  Reka A Haraszti; Andrew Coles; Neil Aronin; Anastasia Khvorova; Marie-Cécile Didiot
Journal:  Bio Protoc       Date:  2017-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.